Introduction
Epileptic seizures due to brain tumors have been described since the 19th century. John Hughling Jackson first reported the direct relationship between seizures and brain tumor. 1 Approximately 30-50% of patients with brain tumors present with seizures as the initial symptom. 2, 3 Seizures play a very important role in the quality of life, particularly in patients with slow-growing primary brain tumors, for whom seizure incidence reaches 80-90%. 2, 4 These seizures often manifest as focal seizures with secondary generalization and are often refractory to antiepileptic treatment. A number of studies have established an association between epileptic seizures at disease onset and a more favorable prognosis. 4, 5 Seizure onset at a later time, however, is frequently associated with neurosurgical procedures or progression of the lesion. 6, 7 Despite the importance of this subject to the fields of neurology, neurosurgery, and neurooncology, the pathogenesis of tumorrelated epilepsy remains poorly understood. At present, there seem to be two schools of thought regarding the pathogenesis of tumor-related epilepsy. One theory is based on the tumor origin: the tumor itself may excrete molecules that could make the tumor tissue epileptogenic, or it could change the peri-tumoral microenvironment and turn this into an epileptogenic zone. The other theory is that the tumor mechanically compresses the surrounding normal tissue, which eventually becomes epileptogenic after suffering from ischemia and hypoxia. Both of these processes could potentially cause secondary changes, such as changes in neurotransmitters and their receptors, metabolic changes, and inflammatory responses, eventually leading to epileptic seizures. However, neither of these theories can fully explain the patterns of seizure incidence. This review attempts to summarize the possible mechanisms of tumor-related epilepsy, based on the hypotheses mentioned above. This knowledge may provide guidance in the search for new strategies for the surgical and medical treatment of tumor-related epilepsy.
Mechanisms

Tumor factors
Histology
Seizures are common in patients with low-grade tumors such as dysembryoblastic neuroepithelial tumors (DNETs), gangliogliomas (GGs), and oligodendrogliomas (OGs). The incidence of epilepsy in high-grade brain tumors such as glioblastoma multi-formes (GBMs) and metastatic tumors is lower. The pathogenesis of seizure development is likely to be different for brain tumors with a different histology. 8, 9 Developmental tumors consist of well-differentiated cells, which are able to release neurotransmitters and other modulators that are involved in epileptogenesis. 10 These tumors may also be associated with structural epileptogenic abnormalities of the cortex. The highly infiltrative growth of fast-growing high-grade brain tumors may damage the subcortical network essential for electrical transmission, 11 whereas slow-growing tumors have been suggested to induce partial deafferentation of cortical regions, causing denervation hypersensitivity 10, 12 and producing an epileptogenic milieu. In addition, gliosis and chronic inflammatory changes in the peritumoral regions may lead to epileptic seizures. Brain tumors with the same grade but a different histology may have different seizure incidences. 6 Furthermore, not all patients with similar tumor localization and histology have seizures. 9 This strongly suggests that genetic factors may play a role in tumor development and tumor-related epilepsy.
Tumor location
The location of the tumor is also an important determinant of tumor-associated epilepsy. Chang et al. 6 reported that subcortical location with tumor growth in deep midline structures was less likely to result in seizures. Some authors 13 also suggested that location and proximity to the cortical gray matter were also important factors in the development of epilepsy in patients with glioma. In general, tumors in the frontal and temporal lobes, as well as in the limbic system, are more likely to cause seizures than tumors in other locations. 6, 14 The location of tumors is closely related to their histology. The majority of glioneuronal tumors occur in the temporal lobe. Duffau and Capelle 15 have provided some evidence that diffuse low-grade astrocytomas and oligodendrogliomas may also have preferred locations. In contrast to malignant gliomas, low-grade gliomas (LGGs) tend to grow in secondary functional areas that are close to, but rarely within, the primary eloquent parts of the brain. Our unpublished data have shown that oligodendroglial tumors were more likely to be located in frontal lobe, whereas astrocytomas were more commonly found in temporal locations. This might be explained by the fact that tumor histology is to some extent associated with the lobe where tumors occur during brain development. Loss of heterozygosity at 1p/19q is closely related to tumor histology in gliomas. In a recent study, 16 we hypothesized that some genes on 19q might be susceptibility genes of glioma-related seizures. It may be postulated that tumor-related seizures have unique characteristics, which may share some common genetic pathways with tumorigenesis.
Blood-brain barrier disruption
The cellular components of the blood-brain barrier (BBB) include endothelial cells, astrocytes, pericytes, neurons, and junctional complexes formed by transmembrane junctional proteins including occludin, claudins, and junctional adhesion molecules. 17 Human and animal studies have suggested that perturbations in neurovascular integrity and breakdown of the BBB lead to neuronal hypersynchronization and epileptiform activity. Relevant molecular changes in brain tumors that affect BBB structure and function include decreased expression of transmembrane junctional proteins 18 and heightened release of vascular endothelial growth factor (VEGF). 19 Diffusion of VEGF into the peritumoral brain may aggravate the edema surrounding the lesion. Stewart et al. 20 reported structural defects in endothelial tight cell junctions surrounding human gliomas. A more recent study 21 suggested that this may be mediated by transforming growth factor b (TGF-b) receptor stimulation, causing activity-dependent accumulation of extracellular potassium, facilitation of N-methyl-D-aspartate (NMDA) receptor-mediated neuronal hyperexcitability, and eventually epileptiform activity. Another study demonstrated 22 that blockade of TGF-b receptors in vivo reduced the likelihood of epileptogenesis. Taken together, these results suggest that pathological disruption of the BBB in brain tumor patients may contribute to seizure activity. It is difficult to define the extent to which BBB disturbances may lead to seizure induction. However, it is generally considered that tumors such as LGGs, which cause BBB disturbances but do not destroy the subcortical network, are likely to cause seizures.
Gap junctions
Communication between adjacent glial cells can take place through transmembrane proteins known as connexins (CX). Astrocytic gap junctions contain CX43, whereas oligodendrocytes express CX32, and neurons express CX26 and CX32. 23 Recently, alterations in glial gap-junctional coupling have been found to be associated with tumoral epilepsy. Aronica et al. 23 demonstrated increased CX43 membrane immunoreactivity in low-grade gliomas when compared with both high-grade lesions and control brain tissue. Furthermore, the perilesional epileptogenic cortex surrounding low-grade lesions contained reactive astrocytes that expressed higher levels of CX43 than control cortex. 23 Interestingly, high-grade gliomas exhibited aberrant intracytoplasmic localization of CX43, 23 which might explain the lower risk of tumorrelated seizures among patients with this type of cancer.
Molecular genetic changes
Genetic factors inside the tumor may also play a role in the epileptogenic process. For example, expression of tumor-suppressor gene LGI1, which could contribute to glioma progression by increasing cell growth and migration when down-regulated, 24 is low or absent in cell lines from high-grade gliomas. 25 Based on the possible association between seizure recurrence and glioma progression, 6, 7 Brodtkorb et al. 26 suggested that LGI1 may be correlated with epileptic susceptibility in patients with brain tumors. However, some other studies have not supported a tumorsuppressor function of LGI1, 27 and further investigations are needed to confirm such a role. Tumors have genomic and chromosomal instability, including DNA strand breaks and rearrangements. These alterations may be associated with changes in gene expression, with negative effects on the stability of DNA repair mechanisms, and this may lead to mutations. Under these conditions, the tumor cells might become epileptogenic. Bordey and Sontheimer 28 reported that astrocytic tumor cells might generate action potentials, which might themselves be the source of epileptic activity. Ye and Sontheimer 29 found that glioma cells released glutamate and caused excitotoxic cell death of the peri-tumoral neurons. These findings suggest that the tumor itself could be an independent origin of epileptogenesis. Further studies of the possible candidate susceptibility genes for tumor-related seizures are encouraged (Figs. 1 and 2).
Peri-tumoral factors
The microenvironment in brain tumors is substantially different from that in normal brain tissue. Contemporary imaging techniques provide testimony to the remarkable differences between the peri-tumoral brain and normal tissue. Recent advances in magnetic resonance spectroscopy (MRS) have demonstrated decreased levels of N-acetylaspartate, a marker of neuronal viability and function, in lesional epileptogenic cortex. 30 Focal abnormalities of low-frequency magnetic activity on magnetoencephalography (MEG) in peri-tumoral regions have been found in 13 of 20 patients with tumor-related seizures. 31 Douw et al. also indicated that pathologically increased theta band connectivity was related to a higher number of epileptic seizures in brain tumor patients, suggesting that elevated theta band connectivity is a hallmark of tumor-related epilepsy. 32 Whether these associations reflect local metabolic imbalances, functional deafferentation, or profound structural alterations remains unclear.
Morphologic changes
Certain morphologic changes in the peri-tumoral brain tissue, such as persistent neurons in the white matter, inefficient neuronal migration, and changes in synaptic vesicles, are also believed to contribute to seizure generation. 8, 33 It is possible, and indeed likely, that peri-tumoral cells have an altered or anomalous phenotype, which is commonly seen in glioneuronal or dysplastic brain tumors. This could be related to the origin of the tumor or could constitute a predisposing factor for seizures in people with brain tumors. Comparison of the ultrastructure of the peri-tumoral cortex in patients with and without epilepsy has demonstrated statistically significant changes in the form, size, distribution, and number of synaptic vesicles. 34 Another type of cellular change suggested to be associated with tumor growth is a decrease in inhibitory synapses and increase in excitatory synapses in peritumoral pyramidal neurons. 35 Dysfunctional astrocytes in peritumoral regions may also contribute to epilepsy through different mechanisms.
36,37
Hypoxia, acidosis and metabolic changes
Hypoxia and acidosis are produced as a result of intratumoral decreased perfusion and elevated metabolism, respectively. However, the relationships between perfusion, hypoxia, metabolism, and acidosis are complex. The growth of brain tumors depends on the establishment of an adequate blood supply. 38 On one hand, tumors with insufficient blood supply often cause interstitial hypoxia, which subsequently contributes to acidosis. This intratumoral hypoxia and acidosis may extend to the surrounding tissue. On the other hand, tumors with large size usually cause peri-tumoral hypoxia because of direct compression. Both these factors could cause glial cell swelling and damage. 39 This is of particular interest because astroglial cells control the acidity of the environmental fluid. Under these conditions, the astrocytic cell membrane becomes prone to inward sodium currents, leading to risk of epilepsy. 40 Furthermore, hypoxia causes acidosis as a consequence of both heightened metabolic requirements of the proliferating tissue and impaired oxidative energy metabolism. The normal response to hypoxia would be glucose catabolism with lactate production, leading to acidosis in metabolically active tissue. With the advent of magnetic resonance imaging (MRI), MRS, and positron emission tomography, many studies have evaluated the metabolic activity in both epileptic and neoplastic brain. Increased lactate levels 41 and decreased glucose metabolism were observed in the peritumoral white matter. An elevated level of lactate compared to healthy tissue has also been reported in tumor tissue. 42 Thus, the epileptogenic changes must have a component that is transferable to the surrounding neurons. However, it is unclear how the metabolic abnormalities described above could be responsible for this, unless they have an effect on neuronal morphology or function.
Ionic changes
Ionic changes in the peri-tumoral zone may influence neuronal activity. Hossmann et al. 43 described elevated sodium and calcium levels in the extracellular peri-tumoral space, which may contribute to neuronal hyperexcitability. Kraft et al. 44 also demonstrated that, under acidic conditions, astrocytoma cell membranes are susceptible to inward sodium currents following sodium channel activation. The relevant family of ion channels has been termed the brain sodium channel complex. 45 Likewise, increased densities and altered gating of calcium channels have been reported in epileptic tissue. Potassium channel mutations (e.g., KCNQ) have been found in certain epileptic syndromes, and extracellular potassium concentrations are thought to play a role in ictogenicity due to their impact on membrane potential. 46, 47 Magnesium (Mg 2+ ) helps to stabilize neuronal excitability by blocking calcium influx through NMDA receptor channels. Avoli et al. 48 demonstrated that decreased extracellular concentrations of Mg 2+ can lead to spontaneous epileptiform discharges and spreading depression in human cortex in vitro. In addition, increased levels of Fe 3+ in intra-or peri-tumoral areas due to small bleedings from pathological blood vessels may also contribute to the development of tumor-associated seizures. This is more likely to occur in high-grade gliomas, since experimental Fe
3+
-induced peroxidative injury to neuronal plasma membranes is related to the development of paroxysmal epileptiform activity. 8, 49 Recently, an interesting hypothesis was proposed by Sontheimer, 50 who suggested that glioma invasion into the peri-tumoral zone is in part mediated by chloride (Cl À ) channel overexpression, allowing cells to traverse the extracellular space through rapid changes in cell shape. Similar mechanisms may be involved in glioma metastasis, to cause seeding and infiltration of the narrow extracellular spaces in the brain. 51 It remains unclear whether seizures represent an associated feature of ion channel overexpression. Further studies are needed to confirm this hypothesis.
Changes in amino acids and neurotransmitter receptors
Previous studies 29, 52 have demonstrated that perturbations in the balance between excitatory and inhibitory compounds may lead to glioma-related seizures. Dysfunctional astrocytes may send signals to neurons by releasing a number of gliotransmitters that can have both excitatory and inhibitory actions.
Glutamate neurotransmission.
Recent work has demonstrated a close link between seizure activity and high extracellular glutamate in tumor-related epilepsy. Patients with glioma and refractory epilepsy have increased concentrations of glutamate, as shown by changes in perilesional immunoreactivity of glutamate decarboxylase. 40, 52 Glutamate is an excitatory neurotransmitter that acts on postsynaptic membranes by interacting with ionotropic and metabotropic glutamate receptors. 53 Glutamate receptors can be present in greater or lesser numbers in tumors, depending on the degree of differentiation and transcriptional control in the tumor tissue. Glutamate activation of ionotropic receptors leads to a rapid excitatory signal based on cation influx that can cause release of calcium from intracellular stores. Ionotropic glutamate receptors include NMDA receptors (NR1, NR2A-C subunits), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (GluR1-4 subunits), and kainate receptors. Aronica et al. 54 examined 41 cases of gangliogliomas and 16 cases of DNETs, all with intractable epilepsy. Both tumor types had higher NR2A and NR2B expression in the tumors than in the nonepileptic cortex. In a similar study, Lee et al. 55 evaluated NMDA receptor expression in 13 patients with DNET and refractory epilepsy. Stronger NR1, NR2A, and NR2B expression with increased GluR2 and GluR3 immunopositivity was found in the peri-tumoral cortex. Aronica et al. 54 also demonstrated elevated expression of kainate receptors in the reactive astrocytes of the perilesional zone. Interaction of glutamate with metabotropic glutamate receptors (mGluR) initiates intracellular signaling through GTPbinding proteins, which can serve neuromodulatory functions. Abnormalities of receptor activation could result from differences in the relative expression in peri-tumoral tissue compared to normal brains. It has been suggested that mGluR2 expression was decreased in the neuronal component of GGs and DNETs, while mGluR5 was expressed at higher levels on reactive astrocytes surrounding those tumors. 54 Rutecki et al. 56 showed that metabotropic receptors might modulate AMPA receptor activation to generate oscillatory calcium waves. This effect could be inhibited by AMPA receptor blocker, but not by NMDA or g-aminobutyric acid A (GABA A ) receptor antagonists. In addition, activation of mGluR5 can lead to phosphoinositolbased calcium signaling. 57 Further investigations of how metabotropic receptor expression is altered in seizure-related tumors will be necessary to validate the pathophysiological roles of these changes.
GABA neurotransmission.
The inhibitory neurotransmitter GABA can inhibit neuronal firing. GABA receptor down-regulation may contribute to hyperactivity of the surrounding microenvironment. GABA receptors are classified as GABA A , GABA B and GABA C receptors. In peri-tumoral tissue, changes in the function of these receptors have been well documented, and mainly involve reduced GABAergic neurotransmission. 55, 58 Labrakakis et al. 59 investigated the responsiveness of glial tumor tissue slices to GABA, and observed a depolarizing response to GABA A receptor activation in 71% of oligodendroglioma cells and 62% of astrocytoma cells. In contrast, no activation by GABA was found in GBM specimens. This indicates that the GABA A receptor is expressed at higher levels in
LGGs compared to GBM, and that responses are often excitatory in tumor tissue. Interestingly, GABA levels appeared to be higher in human tumor-inflicted tissues than in control tissue. 46, 47 Although
GABAergic activity does not directly correlate with seizure susceptibility, it is likely that the changes in transmitter levels are causal for tumor-associated epilepsies. To date, the role of GABA and its receptors in tumor-induced epilepsy is still largely unclear.
Other amino acid transmitters.
Other amino acids may also play a role in tumoral epileptogenesis. Gliomas have been shown to produce lower levels of kynurenic acid, 60 which may lead to disinhibition of NMDA receptors. 61 Decreased levels of noradrenaline and serotonin, which can have intrinsic inhibitory and antiepileptogenic effects, have also been demonstrated in gliomas. 58 
Immunological and inflammatory changes
Several studies have reported an association between strong immunological or inflammatory changes with decreased risks of glioma. 62, 63 Immunological factors are also likely to play a role in tumor-associated epilepsy, and proinflammatory cytokines and their receptors have been suggested to be involved in the pathogenesis of epilepsy. Cytokines, such as interleukin 4 (IL-4) and IL-6, 62 have modulating effects on neurotoxic neurotransmitters that are released during excitation or inflammation in the central nervous system. IL-1b and tumor necrosis factor a interfere with astrocyte gap junction communication. In cell culture, release of these proinflammatory cytokines from activated microglia leads to a closure of CX43-mediated gap junctions in astrocytes. 64 Since status epilepticus induces massive microglial activation in mice in vivo, 65 inhibition of gap junction communication in astrocytes appears to represent a very early alteration in the process of epileptogenesis. In glioma, immune-mediated neurochemical changes by microglia in the peri-tumoral brain regions are well documented. 66, 67 Immune-mediated neuronal damage of the peri-tumoral brain area, coupled with changes in the balance between stimulatory and inhibitory cytokines, may contribute to the development of tumor-related epilepsy.
66,68
Treatment implications for tumor-related epilepsy
Seizures caused by brain tumors often manifest as focal seizures with or without secondary generalization, and approximately one third of patients are refractory to antiepileptic medication treatment. There are a number of possible reasons for the medication resistance. 69 First, antiepileptic drugs (AEDs) could be affected by the biochemical milieu of the peri-tumoral space. Second, significant drug-drug interactions between AEDs and chemotherapeutics may affect antiepileptic effectiveness, and exaggerate side effects by influencing the hepatic cytochrome P450 system. Third, treatment resistance may also arise from overexpression of multidrug resistance-related proteins (MRPs) in tumors, which restrict the penetration of lipophilic substances into the brain. MRPs were found at heightened levels in brain tumor capillary endothelial cells and astrocytes. 69 
How much resection is required?
Based on the presumption that neurons surrounding the tumor constitute the epileptogenic zone, removing the tumor alone may not guarantee a good outcome in seizure control. However, it can also be argued that if the irritating lesion is removed, the microenvironment may return to normal and the surrounding neurons may cease to discharge abnormally. For most surgical series involving pediatric patients, lesionectomy alone yielded very good results. 70, 71 However, studies on adult patients demonstrated that gross total resection or even extended lesionectomy could greatly improve seizure prognosis. 6, 72 One possible reason for the better results of lesionectomy in children may be that their seizure history is shorter with less opportunity of permanent secondary changes such as hippocampal sclerosis. In general, surgeons are encouraged to minimize the residual tumor volume when possible.
Should traditional AEDs be phased out?
No randomized clinical trials have evaluated the efficacy of traditional AEDs, such as valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT) and phenobarbital (PB), in patients with brain tumors. It is difficult to draw firm conclusions from available studies. Hence, the decision of which AEDs to administer to patients with brain tumors is based mainly on individual preference rather than clinical evidence. However, a meta-analysis by Glantz et al. 73 of 12 informative studies investigating the use of prophylactic anticonvulsants (PHT, PB, or VPA) in patients with primary and metastatic brain tumors demonstrated a lack of efficacy in preventing the first seizure or in decreasing the frequency of initial seizures. Temkin also reported that there was no evidence that long-term treatment with PHT and CBZ could protect against late seizures. 74 The question of whether or not the choice of a traditional AED should be solely based on their side effect profile remains to be answered. VPA is thought to inhibit epileptic discharges by stabilizing neuronal membranes and enhancing GABA transmission. It can induce apoptosis, growth arrest, and cell differentiation of tumor cells through inhibition of histone deacetylase. 75 A recent study reported that VPA induced autophagy in glioma cells and this action was independent of apoptosis. 76 A study by Weller et al. also
indicated potential anti-tumor activity of VPA in patients with GBM who required an AED during temozolomide-based chemoradiotherapy. 77 The fact that both tumoral and peri-tumoral factors contribute to the pathogenesis of tumor-related epilepsy suggests that VPA should be considered as a first line therapy in treating tumor-related epilepsy.
What advantages will new AEDs bring?
Newer 82 demonstrated that enhancing the activity of ROMK1 channels, which stabilize the resting membrane potential, may be an important mechanism of LEV in preventing seizure initiation. LEV has been shown to be very effective and well tolerated in patients with brain tumor-associated seizures. In a recent study, the gap junction inhibitor carbenoxolone has been evaluated in organotypic hippocampal slice cultures as a potential antiepileptic agent. It was found that it inhibited both spontaneous and evoked seizure-like events. 83 The clinical utility of this strategy remains uninvestigated, but it is possible that it may be valuable in the context of low-grade gliomas accompanied by elevated CX43 expression.
Conclusions
Epileptic seizures are common in patients with brain tumors. The underlying pathogenesis of tumor-related epilepsy is not effectively addressed by conventional AEDs. To date, the epileptogenic mechanisms of tumor-related epilepsy remain largely unclear. Tumor cells may create internal epileptogenicity through their intrinsic characteristics, and inadequate homeostasis in the peri-tumoral tissue may cause alterations in the balance between excitation and inhibition. Other local changes in electrolytes, perfusion, metabolism, and enzymes could also contribute. It is generally accepted that changes in neurotransmission and extracellular ion concentrations are the most important mechanisms underlying tumor-related seizures. Hypoxia, acidosis, and metabolic, immunological, and inflammatory changes also play potential roles in the induction of seizures. This review has summarized the possible pathogenesis of tumor-associated epilepsy and has also created a framework on which novel therapeutics may be applied (Fig. 3) . Further investigations of both intra-and peri-tumoral pathophysiology may give guidance in the choice of medical therapy. Increased understanding of the dynamic processes at the tumor-brain interface may lead to novel concepts and treatment strategies for tumor-associated epilepsy in the future.
